Genmab A/S (NASDAQ:GMAB) Price Target Raised to $40.00 at HC Wainwright

Posted by Stanley Muller on Jul 2nd, 2026

Genmab A/S (NASDAQ:GMAB – Get Free Report) had its price target increased by stock analysts at HC Wainwright from $38.00 to $40.00 in a note issued to investors on Thursday,Benzinga reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s target price indicates a potential upside of 44.72% from the company’s previous close.

Several other research analysts have also weighed in on GMAB. Truist Financial initiated coverage on Genmab A/S in a research report on Wednesday, May 27th. They issued a “buy” rating and a $40.00 target price on the stock. Weiss Ratings downgraded Genmab A/S from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Friday, May 8th. Wolfe Research assumed coverage on Genmab A/S in a research note on Friday, March 27th. They issued an “outperform” rating and a $32.00 price objective on the stock. BNP Paribas Exane upgraded Genmab A/S from a “hold” rating to a “strong-buy” rating in a report on Wednesday, April 22nd. Finally, The Goldman Sachs Group raised shares of Genmab A/S from a “neutral” rating to a “buy” rating in a research report on Wednesday, April 22nd. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $38.21.

Get Our Latest Report on GMAB

Genmab A/S Stock Up 0.6%

Shares of GMAB opened at $27.64 on Thursday. The firm has a market cap of $17.23 billion, a PE ratio of 20.94, a price-to-earnings-growth ratio of 1.77 and a beta of 0.84. The company’s fifty day moving average is $26.15 and its two-hundred day moving average is $28.69. Genmab A/S has a fifty-two week low of $20.23 and a fifty-two week high of $35.43. The company has a quick ratio of 2.17, a current ratio of 2.18 and a debt-to-equity ratio of 0.87.

Institutional Investors Weigh In On Genmab A/S

Several hedge funds and other institutional investors have recently added to or reduced their stakes in GMAB. Paradigm Biocapital Advisors LP purchased a new position in Genmab A/S in the 3rd quarter valued at about $117,063,000. Orbis Allan Gray Ltd lifted its stake in shares of Genmab A/S by 30.2% in the fourth quarter. Orbis Allan Gray Ltd now owns 14,418,462 shares of the company’s stock worth $444,089,000 after acquiring an additional 3,340,456 shares in the last quarter. Arrowstreet Capital Limited Partnership lifted its stake in shares of Genmab A/S by 36.6% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 4,978,058 shares of the company’s stock worth $153,324,000 after acquiring an additional 1,334,919 shares in the last quarter. First Trust Advisors LP boosted its holdings in Genmab A/S by 84.3% in the first quarter. First Trust Advisors LP now owns 2,461,342 shares of the company’s stock valued at $66,038,000 after purchasing an additional 1,126,069 shares during the last quarter. Finally, Pictet Asset Management Holding SA purchased a new position in Genmab A/S in the fourth quarter valued at about $33,835,000. Hedge funds and other institutional investors own 7.07% of the company’s stock.

About Genmab A/S

(Get Free Report)

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.